February 05, 2019
Rose
Patients suffering from a rare disorder previously were able to obtain the treatment for free from a small pharmaceutical company that offered it through an FDA program called “compassionate use.” In November, the FDA allowed Catalyst to distribute the drug, with exclusive rights to market it. The following month the company said it would sell Firdapse for $375,000 a year. In other news, lawmakers are inviting CEOs from seven major drug companies to testify on prices.
from Kaiser Health News http://bit.ly/2S98XuS
February 05, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
‘We Weren’t Arresting Our Way Out Of Anything’: How Tiny Police Stations Are Revolutionizing Fight Against Opioid Crisis- First Edition: June 4, 2018
- As Anger Brews Over Hurricane Death Toll Discrepancies, Puerto Rico’s Health Department Sued For More Information
- In Turf War Over Physicians’ Practices, Hospitals Are Winning By A Long Shot. But Insurers Are Clawing Back.
- Medicaid Advocates See Virginia’s Expansion Decision As Broader Political Shift
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment